KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitReceivables - NetReceivables Refunds
Ratios

Takeda Pharmaceutical (TAK) Receivables - Other (2018 - 2025)

Takeda Pharmaceutical has reported Receivables - Other over the past 8 years, most recently at $380.5 million for Q1 2025.

  • For Q1 2025, Receivables - Other rose 0.76% year-over-year to $380.5 million; the TTM value through Mar 2025 reached $380.5 million, up 0.76%, while the annual FY2025 figure was $381.1 million, 0.91% up from the prior year.
  • Receivables - Other was $380.5 million for Q1 2025 at Takeda Pharmaceutical, up from $377.6 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $714.3 million in Q1 2021 and bottomed at $377.6 million in Q1 2024.
  • The 5-year median for Receivables - Other is $559.4 million (2023), against an average of $542.5 million.
  • Year-over-year, Receivables - Other plummeted 32.5% in 2024 and then grew 0.76% in 2025.
  • Over 5 years, Receivables - Other stood at $714.3 million in 2021, then fell by 4.68% to $680.9 million in 2022, then dropped by 17.84% to $559.4 million in 2023, then plummeted by 32.5% to $377.6 million in 2024, then grew by 0.76% to $380.5 million in 2025.
  • The last three reported values for Receivables - Other were $380.5 million (Q1 2025), $377.6 million (Q1 2024), and $559.4 million (Q1 2023) per Business Quant data.